Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
Trials|May 9, 2020
Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, et al.
Investigational New Drugs|August 25, 2020
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study)Toshinari Yamashita, Hidetoshi Kawaguchi, Norikazu Masuda, et al.
Trials|June 10, 2020
Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, et al.
Acta Medica Okayama|December 22, 2022
Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer PatientsYuko Abe, Naruto Taira, Kosuke Kashiwabara, et al.
Breast Cancer (Tokyo, Japan)|June 10, 2026
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancerTsuguo Iwatani, Norikazu Masuda, Shigehira Saji, et al.
Breast Cancer Research and Treatment|July 8, 2026
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALDNorikazu Masuda, Shigehira Saji, Yasuyuki Kojima, et al.
Breast Cancer (Tokyo, Japan)|May 25, 2025
Axillary surgery in patients with breast cancer with one to three positive micro- or macrometastases in the sentinel lymph nodes: an observational studyShigeru Imoto, Hiroyuki Yasojima, Takeshi Nagashima, et al.
NPJ Breast Cancer|October 24, 2025
Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic surveyMasahiro Takada, Shigehira Saji, Takayuki Ueno, et al.
NPJ Breast Cancer|June 26, 2026
Prospective observational study of atezolizumab plus nab-paclitaxel in patients with metastatic triple-negative breast cancer: JBCRG-C08/ATTRIBUTETatsunori Shimoi, Nobuhiro Shibata, Masahiro Kitada, et al.
The Lancet. Oncology|April 11, 2022
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trialShigehira Saji, Naruto Taira, Masahiro Kitada, et al.
Pageof 11